JP5653916B2 - 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子 - Google Patents

血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子 Download PDF

Info

Publication number
JP5653916B2
JP5653916B2 JP2011517038A JP2011517038A JP5653916B2 JP 5653916 B2 JP5653916 B2 JP 5653916B2 JP 2011517038 A JP2011517038 A JP 2011517038A JP 2011517038 A JP2011517038 A JP 2011517038A JP 5653916 B2 JP5653916 B2 JP 5653916B2
Authority
JP
Japan
Prior art keywords
vwf
platelets
von willebrand
fviii
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011517038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527301A (ja
JP2011527301A5 (enExample
Inventor
ゲルハルト・ディックナイテ
インゴ・プラグスト
エンリケ・レサ
トルステン・ハース
シュテファン・ツァイトラー
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5653916(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2011527301A publication Critical patent/JP2011527301A/ja
Publication of JP2011527301A5 publication Critical patent/JP2011527301A5/ja
Application granted granted Critical
Publication of JP5653916B2 publication Critical patent/JP5653916B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011517038A 2008-07-10 2009-07-10 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子 Active JP5653916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
DE102008032361.6 2008-07-10
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (3)

Publication Number Publication Date
JP2011527301A JP2011527301A (ja) 2011-10-27
JP2011527301A5 JP2011527301A5 (enExample) 2012-07-26
JP5653916B2 true JP5653916B2 (ja) 2015-01-14

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517038A Active JP5653916B2 (ja) 2008-07-10 2009-07-10 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子

Country Status (13)

Country Link
US (2) US8603979B2 (enExample)
EP (1) EP2310043B2 (enExample)
JP (1) JP5653916B2 (enExample)
KR (1) KR20110043654A (enExample)
CN (1) CN102088999A (enExample)
AU (1) AU2009268289B2 (enExample)
CA (1) CA2730290C (enExample)
DE (1) DE102008032361A1 (enExample)
DK (1) DK2310043T4 (enExample)
ES (1) ES2395855T5 (enExample)
PL (1) PL2310043T5 (enExample)
RU (1) RU2563236C2 (enExample)
WO (1) WO2010003687A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AU2008345135C1 (en) 2007-12-28 2015-04-30 Takeda Pharmaceutical Company Limited Recombinant VWF formulations
EP2300497B1 (en) * 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN103919736A (zh) 2008-10-21 2014-07-16 巴克斯特国际公司 冻干的重组vwf配方
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
DE60042171D1 (de) † 1999-12-24 2009-06-18 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
DK2310043T4 (da) 2022-06-20
PL2310043T3 (pl) 2013-02-28
US9095564B2 (en) 2015-08-04
US20140128325A1 (en) 2014-05-08
JP2011527301A (ja) 2011-10-27
AU2009268289A1 (en) 2010-01-14
PL2310043T5 (pl) 2024-02-05
CN102088999A (zh) 2011-06-08
US8603979B2 (en) 2013-12-10
EP2310043A1 (en) 2011-04-20
AU2009268289B2 (en) 2014-11-06
US20110112023A1 (en) 2011-05-12
CA2730290A1 (en) 2010-01-14
DK2310043T3 (da) 2013-01-07
ES2395855T5 (es) 2022-09-06
RU2563236C2 (ru) 2015-09-20
WO2010003687A1 (en) 2010-01-14
CA2730290C (en) 2017-02-07
EP2310043B2 (en) 2022-05-18
DE102008032361A1 (de) 2010-01-21
EP2310043B1 (en) 2012-09-19
KR20110043654A (ko) 2011-04-27
RU2011104705A (ru) 2012-08-20
ES2395855T3 (es) 2013-02-15

Similar Documents

Publication Publication Date Title
JP5653916B2 (ja) 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子
Franchini The use of desmopressin as a hemostatic agent: a concise review
Moore et al. Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography?
Svensson et al. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
US20030180282A1 (en) Method of treatment of thrombotic events
Ozier et al. Pharmacological agents: antifibrinolytics and desmopressin
HU219595B (hu) Von Willebrand-faktort tartalmazó koncentrátumok alkalmazása trombózis elleni szerek és/vagy fibrinotikus szerek okozta vérzésnél antidotumként ható szer előállítására
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
Levy Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas
Rodriguez-Lopez et al. Disordered Hemostasis and Renal Disorders
Taylor Antiinflammatory effects of aprotinin
Khamis et al. Combined administration of tranexamic acid and vitamin K proved perioperative blood loss reduction with cementless total hip replacement
Mizuno et al. Inhibitory effect of activated protein C on cerebral vasospasm after subarachnoid hemorrhage in the rabbit
Zotz et al. Procoagulant drugs
Fogarty Disorders of Hemostasis, II
Dutia et al. Perioperative management of hemostasis
Vitamin The causes of coagulopathy are multiple and can be classified into congenital and acquired causes as follows
Ziakas et al. Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
EP3535390A2 (en) E-we thrombin analog and fibrinolytic combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141119

R150 Certificate of patent or registration of utility model

Ref document number: 5653916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250